Myelodysplastic Syndrome Patients with Disease Progression after Cytoreductive Therapy Have Poor Survival and High Non-Relapse Mortality after Full-Intensity Allogeneic Hematopoietic Cell Transplantation
Year: 2014
Type: article
Abstract: Many patients with myelodysplastic syndrome (MDS) undergo cytoreductive chemotherapy to reduce the marrow blast count prior to allogeneic hematopoietic cell transplantation (HCT). While pre-HCT disease burden correlates with post-HCT outcome, a dynamic approach of assessing changes in blast count with therapy has not been systematically explored.
Institution: Cleveland Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2066497968